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[57] ABSTRACT 
Compositions for treating tissue damage from ischemia 
contain PBN, or active derivatives thereof, which are 
active during ischemia in preventing ATP depletion of 
the cells which predisposes them to subsequent injury 
during reperfusion, and which are active during reper 
fusion as oxygen radical scavengers, in a suitable phar 
maceutical carrier for systemic or local administration, 
especially to the CNS, spinal column and eyes. Based on 
animal studies, the dosage for treating damage due to 
stroke is in the range of 10 to 300 mg/kg. Similar dos 
ages are useful in treating damage resulting from free 
radical generation during in?ammation, either as a 
product ofinfection or exposure to inflammatory agents 
or abusive agents, including drugs and alcohol. 
18 Claims, 5 Drawing Sheets 
US 
LOCOMOTOR ACTIVI Y C UNTSLO OMOT R ACTIVI Y(C UN S/HOUR)
. Patent June 18, 1991 0 Sheet 1 of 5 5,025,032 
3500 3500 
3000* I -3000 
2500- T 2500 
2000- I -2o00 
1500- O l\, -1500 
1000— \5 "1000 
500- l —500 
O I i 0 
con SAL 32 100 300 
PBN DOSE ( mg/kg) 
F/GURE I 
900 900 
- 0-0 CONTROL _ 800 I I A——A 32 PBN 800 
700- I—I 100 PBN —700 
\0 0——0 300 PBN 
e00 ~e00 
500- l I -5o0 
400- L \Q -400 
300- \ -300 
200- ,\ \ \l -200 
O 
100- 1\; -100 
10 20 30 
SUCCESSIVE 10 MIN INTERVAL 
*F/GURE 2 

US. Patent June 18, 1991 Sheet 3 of 5 5,025,032 
1200 I 
O / 
223.9 1000 
OZ 
O3 800- l%' ‘ 
3U /8/87@£ 
I gm; soo~ V7ZQ£V/ ‘'> 
'55 400- ‘/ 
D4 ' 
g 200 
U 
0 1 2 3 4' 5 s 
SUCCESSIVE 10 MINUTES PERIODS 
I—I SALINE 
O—O 1000mg/kg ‘——‘ 32mg/kg 
v——v 2000 mg/kg 0—0 100rng/kg 
v-—' 300mg/kg 
F/GURE 5 ' °—° 500mg/kg 
120 
100‘ _ ' ' _ _ — ' - ‘ - — _ - _ _‘ Q 
80~ STROKE \ LETHALITY 
~° ‘ SURVIVA 
: 60 x WITH L < - PBN 
g 40- //% 3» SURVIVAL % \ 
2o- o %/ \\ 
SALINE PBN 
300 mg /kg 
F/GURE 6 
US. Patent June 18, 1991 Sheet 4 of 5 5,025,032 
0 o 2 
CARBONYL 
PROTEIN IN 
STROKED" 180 
REPERFUSED 
ANIMALS 
D N .U 0 R G K c A 8 
CARBONYL 
PROTEIN 
O 6 4
1.01.?200 m0x.
O 2 
100 
ISCH I5 MIN. 60 MIN. ‘ PBN 
300 mg/ kg 
F/GURE 7 
100 
PROTECTION 
BY PBN 
O o8 7
JOmFZOU m0
o 6 
ISCH 15 MIN. 60 MIN. PBN 
300 mg/kg 
US. Patent ‘June 18, 1991 Sheet 5 of 5 5,025,032 
145 
E i r = 0.90 
2 
9 
O. 
U 
E 
\ 
3 
C 
O 
.0 
l 
O 
O 
[I] 
5 T ‘ 
1.500 2.000 2.500 
as SPECIFIC ACTIVITY 
U Control 
I! 10: ischemicl, n0 reper'rusion 
w 10 ischemi0,15 reper’rusion 
l . . l . 
! 1OI |_schem|'0,6O' repertuslon 
I 10 |schem10,6O repertusion 
+ PBN 
5,025,032 
1 
PHENYL BUTYL NITRONE COMPOSITIONS AND 
METHODS FOR TREATMENT OF OXIDATIVE 
TISSUE DAMAGE 
BACKGROUND OF THE INVENTION 
This is generally in the area of compositions and 
methods for use thereof for the treatment of oxidative 
tissue damage such as that resulting from ischemia or 
in?ammation, wherein the active compounds are 
phenyl butylnitrone (PBN) or derivatives thereof. 
Oxygenated tissue suffers damage, in many cases 
permanent damage, if it becomes ischemic and is then 
reperfused. Oxygen free radicals have been implicated 
in the injury. Brain appears to be uniquely susceptible to 
ischemia/reperfusion injury, and neurons are more sus 
ceptible than glial cells. Certain areas of the brain, for 
example, the hippocampus and spinal cord, are more 
susceptible than other regions of the brain. As a result, 
ischemia/reperfusion injury to brain may have a multi 
plicative effect simply because of the necessity for com 
plete integrity of all regions in order to have proper 
functioning. - 
Several mechanisms may cause ischemic brain dam 
age. For example, the mechanisms responsible for selec 
tive neuronal vulnerability may be different from those 
that cause glial swelling and extensive brain edema, and 
a third set of events may underlie such gross functional 
aberrations as seizures. Siesjo, Critical Care Med. 16, 
954-963 (1988), has grouped the numerous observations 
into four possible mechanisms to explain the injury in 
brain. These include: (A) calcium mediated cell death, 
(B) excitotoxic damage (glutamate buildup), (C) free 
radical events and (D) acidosis. It is likely that all four 
basic mechanisms are either interrelated or contribute 
collectively to the injury observed. 
It now seems likely that selective neuronal vulnera 
bility is, at least to some extent, an excitotoxic lesion 
that is triggered by the release of glutamate and/or 
aspartate from depolarized nerve endings. At the mem 
brane and molecular levels, calcium influx via NMDA 
activated channels is probably crucial, although os 
molytic damage to dendritic spines and dendrites could 
contribute. It has never been satisfactorily explained, 
however. how ischemia could cause delayed neuronal 
death. 
The mechanisms that cause laminar necrosis, glial 
destruction, and infarction are more speculative. The 
inability of the cells to regulate their volume may be 
caused by a molecular defect where edema is a conspic 
uous feature. Cells that possess coupled antiporters for 
Na+/H+ and Cl—/HCO3 exchange may regulate pHi 
at the expense of volume regulation, so that edema may 
be coupled to acidosis. 
When ischemia is accompanied by a delayed acidosis 
related damage, it seems likely that the lowering of pH 
causes changes in protein structure and function, which 
~‘mature” with time and ultimately cause gross mem 
brane dysfunction. It is tempting to assume that the 
primary lesion is an iron-catalyzed free-radical damage 
to membrane components, enhanced by the drastic 
lowering of pHi and/or pHe. 
Free radicals have been postulated to be mediators of 
reperfusion damage. The important production sites of 
such radicals as the superoxide (Og—) and hydroxyl 
(OH) species are the mitochondrial respiratory chain 
and the sequences catalyzed by cyclooxygenase and 
lipoxygenase. However, radicals are also formed furing 
5 
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autoxidation of many compounds (e.g.. catechola 
mines). Several ischemic events favor a spurt of free 
radical formation, e.g., those causing oxidation of 
polyenoic free fatty acids, release and reuptake of cate 
cholamines, and oxidation of hypoxanthine by xanthine 
oxidase. Although all these events occur during recircu 
lation, when the O2 supply is restored, they represent 
metabolic cascades triggered by agonist-receptor inter 
actions, energy failure, and/or calcium influx during the 
insult. Although free radical formation is a likely cause 
of ischemic damage, it has been difficult to directly 
demonstrate that such formation occurs and/or that it is 
sufficiently pronounced to overwhelm the antioxidative 
defense of the tissue. Curran, et al., M01. Cell. Biol. 5. 
167-172 (1985). In recent years, however. evidence has 
been obtained that ischemia may cause conjugated di 
enes and malondialdehyde to accumulate in the tissue. 
Nonetheless, it remains to be conclusively shown that 
' free-radical damage to unsaturated acyl chains in phos 
pholipids, to protein. or to nucleic acids constitutes an 
important part of the ischemic necrosis. At present. the 
evidence is relatively strong for an involvement of free 
radical mechanisms in vascular injury. but not for dam 
age affecting nerve and glial cells. 
Reviews by Hall and Braughler. Free Radical Biol. 
Med. 6, 303-313 (1989), Kontos, Physiology ofOxygen 
Radicals, ed. Taylor, Matalon and \Vard. pp. 207-216 
(Am. Physiol. Soc, Bethesda. MD 1986). and Ernster. 
Critical Care Med. 16, 947-953 (1988). document a sig 
ni?cant amount of evidence implicating oxidative dam 
age in head and spinal cord injury as well as in hemor 
rhagic stroke and ischemic stroke. Most research which 
strongly implicates the primary role of oxidative dam 
age in ischemia/reperfusion injury in brain can be 
grouped into either oftwo types ofstudies: those which 
show protection by addition of agents preventing 
peroxidative events, or those designed to observe free 
radicals. 
Although no drugs are currently approved for clini 
cal use in treating tissue damage due to ischemia. sev 
eral compounds have been proposed as potentially 
being effective. Mannitol, an osmotic agent and an oxy 
gen scavenger. has been added to reperfusion media and 
may limit damage to organs for transplantation. Super 
oxide dismutase (SOD) has been suggested as a means 
for limiting in vivo oxidative damage. The most promis 
ing compounds that interfere with peroxidation genera 
tion are the lazaroids, modi?ed prednisones, described 
by J. M. McCall. Acta Anesthesia Belgica, First Antwerp 
Int. Trauma Symp., which have been reported to be 
efficacious if given during or after ischemia. For exam 
ple, Hall, et al, Stroke 19, 997-1002 (1988), demon 
strated that the 21-aminosteroid (474006F), which is 
known to prevent peroxidation in brain homogenate, as 
described by Braughler, et al., J. Biol. Chem. 262. 
10438-10440 (1987), protected gerbils against brain 
damage induced by three hours of unilateral carotid 
artery occlusion. White and Aust and co-workers, Adv. 
Free Radical Biol. Med. 1, 1-17 (1985). and Babbs. Re 
suscitation 13, 165-173 (1986), have demonstrated that 
iron chelators protect animals from ischemia/reperfu~ 
sion injury. 
With regard to direct demonstrations of oxidative 
events during ischemia/reperfusion injury in brain. 
there are pertinent observations using spin-trapping 
techniques. salicylate hydroxylation. protein oxidation. 
and nucleic acid oxidative damage. Spin-trapping has 
5,025,032 
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provided clear evidence implicating free radical pro 
duction during ischemia/reperfusion injury. Imaizumi, 
et al, Neurological Res. 8. 214-220 (1986), showed that 
the spin-trap PBN when incubated with rat brain ho 
mogenate of animals which had experienced very low 
oxygen pressure for 5 min was able to trap an appar 
ently lipid-type radical. Kirsch, et al, Pediatric Res. 21, 
202A (1987), stated in a preliminary note that PBN had 
trapped free radicals in post ischemic brains from ani 
mals pretreated with the spin-trap. McCay‘s group have 
spin trapped free radicals in mouse brain, Arch. Bio 
c/zem. Biophys. 244, 156-160 (1986), and shown that 
spin-trapped free radicals of PBN are present in blood 
leaving the heart of intact dogs recovering from a 
“stunned“ myocardiurn, J. Clin. Invest. 82, 476-485 
(1988). As described, the free radicals spin-trapped are 
apparently lipid-type free radicals and appear within 1 
min after release of occlusion and reach peak intensity 
about 5 min after reperfusion starts. PBN enhanced 
recovery of the post ischemic function ofthe “stunned" 
heart. 
In summary, while PBN has been used in a number of 
research studies, there has been no data to support the 
proposition that it could be useful in vivo. particularly 
with respect to treatment oftissue damage in the central 
nervous system. In vivo, the drug must be able to (I) 
cross the blood brain barrier and (2) act in a manner 
which reduces tissue damage during or following isch 
emia. 
It is therefore an object of the present invention to 
provide composition and methods for use thereof which 
are useful in preventing or reversing ischemic damage 
in vivo., especially in the CNS. spinal cord and eyes. 
It is a further object of the present invention to pro 
vide compositions and methods for use thereof which 
are useful in preventing or reversing free radical dam 
age in vivo resulting from infection and inflammation. 
It is another object of the present invention to pro 
vide compositions and methods for use which prevent 
energy depletion of cells during ischemia. 
It is still another object of the present invention to 
provide compositions and methods for use which are 
useful in the treatment of a variety of disorders in addi 
tion to those resulting from ischemia. including progres 
sive neuronal loss from disease or drug and alcohol 
abuse and disorders resulting from photooxidation and 
exposure to high pressure or enriched oxygen. 
SUMMARY OF THE INVENTION 
Compositions for treating tissue damage from isch 
emia contain PBN, or active derivatives thereof. having 
the following general formula, in a suitable pharmaceu 
tical carrier for intravenous administration. 
H O“ 
\ / 
C=N__ 
/ \ 
X Y 
wherein: 
X is phenyl or 
(OR)n 
O 
Lu 0 
50 
55 
65 
wherein R is H, 
and n is a whole integer from 1 to 5: or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
II II 
wherein W is C--CH3. NH-C-Z. 
O 0 
II II 
Z is a C1 to C5 straight or branched alkyl group. 
Based on animal studies. the dosage for treating dam 
age due to stroke is in the range of 10 to 300 mg/kg. 
The compositions are administered prior to or during 
ischemia in an effective dosage to prevent or reverse 
predisposition of the cells to damage resulting from 
depletion of ATP (as demonstrated by in vivo NMR) 
and damage from free radical generation following 
reperfusion. The preferred method of administration is 
intravenously in humans for treatment of stroke. The 
preferred method of administration for treating in?am 
mation is by directed delivery to the site of inflamma 
tion. Examples of diseases which can be treated include 
stroke. meningitis. progressive neuronal loss due to 
Parkinson's disease, senile dementia. and drug abuse. 
disorders arising from exposure to high pressure oxygen 
or enriched oxygen environments, and bleeding into 
nervous tissue as a result of trauma. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph of the dose-effect curve for the 
beneficial effects of PBN on transient ischemia-induced 
hyperactivity, plotting locomotor activity versus PBN 
dose in mg/kg. Young adult gerbils were given a single 
dose of PBN 1 hr. before 5 min of bilateral carotid 
occlusion. Twenty-four hours later the change in spon 
taneous locomotor activity was determined. Control 
(con) value represent the level ofexploratory activity of 
a group of normal naive gerbils. Saline (Sal) values were 
determined in gerbils injected with saline 1 hr. prior to 
ischemia. Data presented represent the mean (:SE.) 
for 6 gerbils per treatment group. 
FIG. 2 is a graph ofthe effect of PBN on the levels of 
activity in successive 10 min intervals for the test de 
scribed in FIG. 1. Data presented represents the means 
(:SE.) for 6 gerbils per treatment group: control 
(-O-O-); 32 mg PBN/kg (-A-A) 100 mg PBX/kg 
(-[]-[]-); and 300 mg PBN/ltg (-<>-<>—). 
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FIG. 3 is a graph of the effects of PBN on the post 
ischemic locomotor activity of aged gerbils (greater 
than 20 months of age) tested 24 hrs. after a 2 min period 
of ischemia, as described in FIG. 1. Control (-O-<>-); 
saline (-O-O-); and 300 mg PBN/kg (-A-A-). 
FIG. 4 is a graph of the effects of administration of 
300 mg PBN on 15 min. ischemia-induced changes in 
spontaneous locomotor activity of gerbils, plotting lo 
comotor activity counts versus time (minutes). Saline 
treated group (-O-O-) represents 5 of the 10 control ger 
bils (-(>-<>-) tested. The data for PBN (-A-A-) repre 
sents all 10 gerbils tested. Control values are for 6 ger 
bils. All data are expressed as the mean (:SE). Where 
no S.E. is indicated. it is within the dimensions of the 
symbol. . 
FIG. 5 is a graph comparing cumulative locomotor 
activity counts over successive 10 minute periods for 
non-ischemic animals receiving saline (dark 32 mg 
PBN/kg (dark A); 100 mg PBN/kg (.); 300 mg PBN/kg 
(dark inverted A); 500 PBN/kg (dark O); 1000 mg 
PBN/kg (O); and 2000 mg PBN/kg (inverted A). 
FIG. 6 is a bar graph comparing percent survival 
after a lethal occlusion of the carotid arteries in gerbils 
treated with either saline or 300 mg PEN/kg. 
FIG. 7 is a graph comparing the percent carbonyl 
protein of control in gerbils that have been subjected to 
ischemia. ischemia followed by 15 minutes reperfusion. 
ischemia followed by 60 minutes reperfusion, and isch 
emia followed by 60 minutes reperfusion ‘with pre 
ischemia administration of 300 mg PBN/kg. 
FIG. 8 is a graph comparing percent of glutamine 
synthase activity of control gerbils that have been sub 
jected to ischemia. ischemia followed by 15 minutes 
reperfusion. ischemia followed by 60 minutes reperfu 
sion, and ischemia followed by 60 minutes reperfusion 
with pre-ischemia administration of 300 mg PEN/kg. 
FIG. 9 is a graph correlating carbonyl/mg protein 
versus glutamine synthetase speci?c activity, control 
(-[]- []-); 10 minutes ischemia. no reperfusion (-[in 
verted A]-[inverted A]-), 10 minutes ischemia. 15 min 
utes reperfusion ([A]-[A]-), 10 minutes ischemia, 60 min 
utes reperfusion (-[<>]-[<>]-). and 10 minutes ischemia. 
60 minutes reperfusion and PBN (dark []). 
DETAILED DESCRIPTION OF THE 
INVENTION 
Following ischemia there is a signi?cant increase in 
free radical production (both oxygen and carbon cen 
tered radicals). The initial damage to brain cells is 
thought to result from the peroxidation products with 
subsequent damage from secondary (carbon-centered) 
radicals. Eventually the metabolic and synthetic path 
ways are damaged to such an extent that the cell dies. 
PBN and functionally equivalent spin trapping deriva 
tives that pass through the blood brain barrier, prevent 
cell damage during and subsequent to ischemia by de 
creasing or preventing ATP depletion. and still exhibit 
spin trapping of oxygen radicals are of bene?t by bond 
ing to the carbon-centered-free radicals to prevent fur 
ther damage by the modi?ed enzyme or other constitu 
ent. As used herein, a free radical scavenger or spin trap 
reagent is a molecule that will form a stable complex 
with a free radical. A free radical carbon trap is a mole 
cule in which the free radical is localized on a carbon 
atom or a nitrogen atom. 
a-phenyl t-butyl nitrone (PBN), and derivatives 
thereof. in a pharmaceutical vehicle suitable for intrave 
nous administration are useful in preventing or revers 
15 
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ing CNS damage following ischemia or inflammation. 
As used herein, ischemia is de?ned as a blockage of 
blood flow that results in a lesion in the central nervous 
system (CNS), including the spinal column and eyes. 
PBN has a number of advantages in the treatment of 
ischemia induced damage. including being able to pass 
through the blood brain barrier and having no measur 
able effect on normal or uninjured cells. PBN is the 
preferred active compound at this time. although a 
number of derivatives are also useful, including hy 
droxy derivatives, especially 2-. 3- or 4-hydroxy PBN 
and mono-, di- and trihydroxy tert-butyl nitrone: esters. 
especially esters which release 2-, 3. or 4-hydroxyphe 
nyl t-butyl nitrone such as the acetoxy derivative. 2-. 3-, 
or 4-carboxyphenyl t-butyl nitrone. such as the ethyl 
derivative, or phenyl hydroxybutyl nitrone. such as the 
acetoxy derivative; alkoxyl derivatives. especially alk 
oxyl derivatives which release 2-. or 4-hydroxyphenyl 
t-butyl nitrone, such as the methyl derivative; and acet 
amide derivatives. especially acetamide derivatives 
which release 2-, or 4 aminophenyl t-butyl nitrone. such 
as the acetyl derivative; diphenyl nitrone (PPN) and the 
analogous diphenyl nitrone derivatives. As used herein. 
“PBN" refers to both a-phenyl t-butyl nitrone and de 
rivatives thereof. unless otherwise stated. The active 
agent in the compositions is N-tert-Butyl-a-phenylni 
trone (PBN) or derivatives thereof that are spin trap 
reagents and which also act to prevent ATP depletion 
of cells. 
The general formula for PBN and useful derivatives 
thereof is: 
H O' 
/ 
C=.\' 
/ \ 
X Y 
wherein: 
X is phenyl or 
(ORm 
wherein R is H. 
and n is a whole integer from 1 to 5: or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions: phenyl; or 
O 
O W 
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-continued 
ll ll 
wherein W is C-CHg. NH-C-Z. 
0 
ll 
C-Cl-b. C-OZ, or Z; and 
Z is a C] to C5 straight or branched alkyl group. 
The compositions can also contain other active 
agents, such as tissue plasminogen activator, streptokirt 
ase, or other clot dissolving compounds, other com 
pounds which are oxygen radical scavengers such as 
mannitol or compounds which prevent peroxidase gen 
eration, such as the lazaroids. 
Examples demonstrate the utility ofthe compositions 
in preventing brain damage and death in animals follow 
ing blockage of blood flow through the carotid artery 
to the brain. Exemplary dosages of PBN ranged from 32 
to 300 mg/kg of body weight in gerbils. The effective 
range of PBN in humans and other mammals is between 
approximately 10 and 300 mg/kg. The compositions can 
be effectively administered prior to, during or after 
ischemia. and prevent or decrease the extent of cellular 
damage. 
The use of compounds which are spin-traps that are 
capable of scavenging oxygen radicals during reperfu 
sion following ischemia. and which act to block ATP 
depletion of the cell (which predisposes the cell to in 
jury following ischemia), represents a truly unique ap 
proach to the management of post-ischemic pathologic 
conditions. and following ischemia associated with sur 
gical procedures (e.g., by-pass surgery and transplanta 
tion of organs). Since the trapping of endogenous free 
radicals is speci?c for only those cells that have been 
exposed to the conditions that result in the production 
of free radicals. the traps will have little or no effect on 
normal cells. The bene?cial effects will occur only in 
injured cells. Moreover, because the bene?cial effect 
does not require the presence of speci?c receptors or 
speci?c enzymes, the spin traps offer a signi?cant im 
provement in the treatment of ischemia/induced cellu 
lar dysfunction and necrosis. 
In addition. these compounds should be extremely 
useful for the prophylactic treatment of chronic or 
periodic cytotoxic conditions that involve free radicals. 
The CNS disease conditions that are expected to be 
treatable using such compounds include stroke, tran 
sient ischemic attacks, Alzheimer necrosis, continued 
cell loss in Parkinsonism, meningitis, cardiac resuscita 
tion-induced brain damage, and damage arising as a 
result oftrauma. especially head and spinal injuries with 
associated bleeding from surrounding tissues into the 
nervous tissues. It is expected that these compositions 
can also be used to treat a variety of other disorders 
including damage resulting from exposure to high pres 
sure oxygen or oxygen - enriched environments, espe 
cially damage to the eyes resulting from placing very 
premature babies on high oxygen respirators, drug and 
/or alcohol abuse - induced damage to the CNS, as well 
as other organs, and damage resulting from exposure to 
ionizing radiation or photooxidation. 
The PBN is preferably administered systemically, 
most preferably intravenously, or orally, since this is the 
most rapid and ef?cient means for directing the active 
compound to the site of free radical generation. How 
ever. other methods of administration can be used, as 
when PBN is administered intraperitoneally in the ex 
35 
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amples. or intranasally through the pulmonary tract. 
The PBN can alternatively be administered locally. by 
intramuscular or subcutaneous injection. ointment. or 
delayed release implant. 
Preferred pharmaceutical carriers for intravenous 
administration are saline or phosphate buffered saline at 
physiological pH. In the preferred method, PBN is 
delivered to the patient intravenously in a dosage in the 
range of 10 mg/kg/hr. most preferably in the range of 
one to three mg/kg/hr. The dosage can be determined 
for the speci?c disease condition and/or species by 
conducting measurements, as described in detail below._ 
In general, an effective dosage is that amount of PBN 
that reduces enzyme activity loss by 25%. decreases cell 
death by 25%, and/or maintains 25% or more of normal 
function. 
The present invention will be further understood 
with reference to the following non-limiting examples 
demonstrating methods for determining effectiveness of 
PBN administration for treatment of injury arising from 
ischemia or inflammation and demonstration in animals 
of the prevention and/or reversal of damage from isch 
emia. 
Gerbil Stroke Model 
An accepted animal model for determining the effect 
of a compound on injury arising from a stroke is de 
scribed by Chandler. et al.. J. Pharm. .Vfc’I/IOG'S l4. 
137-146 (1985). Briefly. Mongolian gerbils are anesthe 
tized with pentobarbital (40 mg/kg). A ventral midline 
incision is made in the neck. Common carotids are ex 
posed and separated from the vagosympathetic nerve 
trunk. A loop of unwaxed dental floss (Johnson and 
Johnson) is placed around each carotid. The ends ofthe 
floss are each passed through one of the lumens of a 
double lumen catheter (Dural Plastics and Engineering. 
Dural, NSW. Australia). The catheter and dental ?oss 
are passed through the dorsal musculature and exited at 
the dorsal surface of the neck. The catheter is ?xed in 
position, directly above the carotid artery. using cyano 
acrylate adhesive at the exit site. The dental floss length 
is marked in order to assure that the animal does not 
occlude the carotid during daily cleaning and explor 
atory activity. The ventral incision is closed with 9 mm 
wound clips. After 48 hrs following instrumentation, 
ischemia is produced by gently pulling the looped den 
tal floss until the artery is occluded. Occlusion of the 
artery is associated with loss of consciousness. ptosis 
and a change in breathing pattern. Previous studies, 
using direct observation, have demonstrated that com 
plete interruption of flow occurs under these condi 
tions. The occlusion is maintained for 10 minutes and 
then the dental floss removed to allow complete reper 
fusion. After reperfusion, the catheter is trimmed flush 
with the surface of the neck. ' 
The animals. male gerbils (50—6O gms). are purchased 
from Tumblebrook Farm. West Brookfield. Mass. and 
housed in groups of three for at least one week prior to 
‘instrumentation. Following surgery, the gerbils are 
singly housed in order to avoid the possible accidental 
induction of ischemia by cage mates. Food and water 
are available ad libitum in the home cage. All gerbils are 
maintained under a 12 hr light/dark cycle. 
5,025,032 
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EXAMPLE 1 
Determination ofthe Extent of Peroxidation Damage in 
Brain Tissue 
Measurement of Tissue Damage by Free Radical 
Generation 
Tissue damage can be measured as a function of the 
generation of free radicals, protein carbonyl concentra 
tion increase, and decrease in glutamine synthetase en 
zymatic activity. 
Free radicals are found in ischemia/reperfusion in 
jured gerbil brains. There are several methods effective 
for measuring the generation of free radicals, including 
spin trapping and salicylate hydroxylation. Salicylate 
hydroxylation can be used to monitor hydroxyl free 
radicals in vivo. since hydroxylation products (2,5-and 
2,3-dihydroxybenzoic acids, DHBA) are present in the 
brains of gerbils pretreated with salicylate. The amount 
of DHBA correlates closely with the amount of brain 
injury observed in this model, as shown by Cao, et al., 
Neuroscience Le”. 88, 233-238 (1988). Oxidative dam 
age to gerbil brain proteins can be assessed by protein 
carbonyl group increase, which occurs as the ischemic 
lesioned gerbil brain is allowed to reperfuse. Overall 
tissue necrosis is also indicated by a decrease in the 
enzymatic activity of glutamine synthetase (GS) in is 
chemic-lesioned gerbil brain. This decrease increases as 
reperfusion time increases, such that at 60 min the GS 
activity is decreased about 35% from normal values. 
The enzymatic activity of GS is highly sensitive to 
metal catalyzed oxidative damage. Therefore its loss 
supports the notion that metal catalyzed oxidative dam 
age does occur in the reperfusion phase of the ischemic 
lesioned gerbil brain. GS enzymatically converts gluta 
mate to glutamine and thus a decrease in its activity may 
allow the buildup of glutamate, an excitatory toxic 
amino acid. 
Utilizing the ischemia/reperfusion lesioned brain of 
gerbils. it was demonstrated that oxidative damage was 
occurring. with the evidence as follows: (1) increased 
levels of salicylate hydroxylation products. implicating 
increased hydroxyl free radical flux in lesioned brain, 
(2) increased levels of protein oxidation and a loss of 
glutamine synthetase activity in lesioned brain, (3) free 
radical formed from spin-traps in lesioned brains. (4) 
spintrap mediated protection from brain ischemia/ 
reperfusion injury, and (5) an increased peroxidation 
capacity of brain during the reperfusion phase after an 
ischemic insult. 
Demonstration of in Vivo Oxygen Free Radical Flux 
by Spin-Trapping and HPLC with Electrochemical 
Detection 
Spin-trapping and HPLC with electrochemical de 
tection (LCED) are used to quantitate hydroxylation 
products of salicylate, formed in part by hydroxyl free 
radical addition, and hydroxyl free radical adducts to 
DNA and RNA. The extreme sensitivity of the LCED 
methodology, on the order of 103 to 104 gain over opti 
cal methods. is a distinct advantage when attempting to 
ascertain the flux of oxygen free radicals in vivo. which 
may only reach IO—° M under high oxidative stress 
conditions. It has been demonstrated in biochemical 
systems that OH radicals could be trapped by salicylate 
and quantitated using LCED. 
Electron spin resonance of brain lipid extract is mea 
sured as follows. Gerbils are administered spin-trap 
dissolved in saline stored cold (protected from light) 
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[.P. 1 hr prior to treatment. Gerbils are given an is 
chemia/reperfusion treatment. or in the case of sham 
operated controls. placed in the animal holder but not 
occlusion, for a de?ned period. The gerbils are killed by 
decapitation. The brains are removed and placed on a 
cooled stage within 2 min. The cortex of brain is iso 
lated cold and stored at -—80° C. for about one week 
until it is extracted. The cortex is homogenized at ice 
temperature in a 0.5% NaCl solution (5 gm/ml) and the 
homogenate is then extracted with 2:1 chloroform 
methanol mixture (v/v) to a final dilution of 20~fold the 
volume of the tissue sample. The crude extract is 
washed thoroughly with 0.5% NaCl (5:1, v/v) and the 
mixture is allowed to separate into two phases by stand 
ing at 4° C. for 2 hr. The organic phase is recovered and 
bubbled with N3 to obtain a concentration that is needed 
or the solvent of the organic phase is evaporated to 
dryness and the residue redissolved in chloroform. Fi 
nally. the samples are transferred to a Pasteur pipette 
(sealed at the capillary end) and bubbled with N3 for 5 
min. The pipettes are then placed in the sample cavity of 
an IBM Bruker ESP3OO EPR spectrometer and scanned 
for the presence of spin adducts. The usual spectrome 
ter settings are as follows: Microwave power 19.8 m\\': 
modulation amplitude 0.975G. time constant 1310.72 
ms; scan range 100 G; and scan time 6 min. All spectra 
are recorded at room temperature. The coupling con 
stants can be directly obtained from the instrument and 
since since the instrument is controlled by an online 
computer. simulated spectra of a mixture of spin 
trapped free radicals can be compared with the bona 
fide spectrum obtained in order to make prediction 
regarding the trapped free radicals. An extensive data 
base of spin coupling constants‘taken in different sol 
vents using different systems is used for comparison 
purposes. 
Spin-traps react with free radicals to form adducts. 
the electron spin resonance (ESR) spectrum. which 
provides a mechanism to deduce the chemical identity 
of the free radicals trapped. The method used for in 
vivo spin trapping was developed by Dr. P. B. McCay 
in combination with Dr. Ed Janzen. as reported by Lai. 
et al., Arch. Biochem. Biop/zys. 2-14. 156-160 (1986). Free 
radicals have been spin-trapped in ischemia/reperfusion 
injury in rat heart by Bolli and McCay. J. C/i'n. Invest. 
82, 476-485 (1988). 
The production of free radicals during ischemia/ 
reperfusion induced injury in the gerbil brain was tested 
using spin trapping. Both treated and control animals 
- were administered the spin trap PBN (ct-phenyl-t-butyl 
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nitrone) before the experimental treatments. The data 
demonstrate that large free radical signals were ob 
tained from the extracts of brains of ischemia/reperfu 
sion treated gerbils in contrast to very little signals from 
sham-operated control animals. Surprisingly, the radi 
cals are not what would be expected when a spin-trap 
reacts with a free radical to produce a spin adduct. A 
six-line spectrum is expected from the spin-adduct of a 
free radical of PBN. The six-line spectrum is due to the 
free electron interacting with the spin % nuclear mag 
netic moment ofthe proton as well as the spin of 1 from 
the nitrogen of the nitroxyl group. In contrast. these 
spectra are only three lines. and are therefore due to the 
free electron interacting with the nitroxyl nitrogen 
only. which means that available protons are displaced 
at a distance such that they are not influencing the free 
electron. 
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The most likely explanation for the results is that 
PBN first traps a free radical, possibly a lipid carbon 
free radical. after which the spin-adduct is then oxidized 
to a nitrone which then traps another free radical, yield 
ing a nitroxide having properties producing the ob 
served spectra. 
Two other spin-traps, DMPO (5,5-dimethylpyrro 
line-N-oxide) and POBN (ot-pyridyl-l-oxide-N-t-butyl 
nitrone), both of which have different chemical struc 
tures from PBN, yielded nitroxide spectra (very similar, 
3-lines, yet with slightly different nitrogen coupling 
constants and different intensities) as with PBN in the 
ischemia/reperfusion treated gerbils. It is pertinent to 
note that if the chloroform/methanol extract of brains 
of animals which have been pretreated with PBN is 
allowed to stand at room temperature for 24 hours, then 
the 3-line signal decays. If, however, more PBN is then 
added to the extracts and it is then incubated for 24 
hours, trapped radial signals are observed in the extract 
ofischemic/reperfusion animals. but signals are not seen 
in the sham-operated controls. Computer simulation of 
the signals developing show that three free radicals are 
present. One has parameters equivalent to the three line 
nitroxide observed previously and the other two are 
spin-trapped carbon free radicals, possibly lipid radi 
cals. These observations indicate that oxidative events 
were started in the ischemic brains but not in the sham 
operated controls and these events are carried over, at 
least in part. in the lipid extracts. 
Demonstration of Ischemia/Reperfusion Induced 
Increased Peroxidation Capacity of the Brain 
Brain homogenate at ice temperature does not spon 
taneously peroxidase. yet if the temperature is raised to 
37° C. there is, in contrast to almost all other tissue 
homogenates. spontaneous peroxidation. The rate of 
peroxidation varies with brain region and is highly cor 
related with the total iron content of the brain region. 
Gerbil brain homogenate peroxidizes more rapidly than 
rat brain. The susceptibility to peroxidation of brain 
homogenate after it has experienced an ischemia/reper 
fusion insult and the effect of time of reperfusion was 
determined. The data were collected from 176 gerbils. 
At every time point sham-operated animals were used 
as controls. The data show that after 10 min ofischemia 
there is. if reperfusion is not allowed to occur. a de 
crease in the rate of peroxidation. If reperfusion is al 
lowed to occur after ischemia, then the rate of peroxida 
tion increases significantly over sham-operated control. 
animals in a time-course fashion. The increase is most 
rapid in the first 60 min then slows, reaching a maxi 
mum at 7 days following ischemia. after which it de 
creases to values which were still higher than controls 
at 14 days. 
Brains from gerbils which have been pretreated with 
pentobarbital and then given a 15 min ischemia period 
followed by 15 min reperfusion have no increase in the 
amount of spontaneous peroxidation above sham 
operated controls. Thus not only does pentobarbital 
protect gerbils from the damage brought about by is 
chemia/reperfusion injury. there is no increased peroxi 
dation of the brain homogenate from pentobarbital 
treated animals as compared with untreated animals. 
Pre-treated animals lesioned by 15 min ischemia/l5 min 
reperfusion had spontaneous brain homogenate peroxi 
dation about 15% above sham-operated controls. dem 
onstrating a direct correlation between increased brain 
homogenate peroxidation. 
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EXAMPLE 2 
Demonstration ofthe Protective Effect ofSpin-Traps in 
Ischemia/Reperfusion Induced Brain Injury in Gerbils 
The spin-trap PBN offers considerable protection to 
the gerbil from brain injury brought on by an ischemia/ 
reperfusion insult and in addition helps prevent death 
which often accompanies the brain injury. The data 
demonstrating these statements are presented in FIGS. 
1. 2. 3 and Table 1. Table 1 shows that animals given 
PBN I.P.. dissolved in saline, at a dosage of 300 mg/kg, 
60 min prior to 15 min ischemia, which is followed by 
24 hr reperfusion, protected the animals from death. 
that is, the animals lived for longer than 7 days, the time 
point when lethality is evaluated. Ofthe control animals 
which received saline. 50% of the yound and 100% of 
the old gerbils had died as of the seventh day. 
Gerbils. which have received a brain ischemic insult 
resulting in permanent injury. first exhibit a lethargic 
reaction then a characteristic increase in spontaneous 
locomotor activity above controls at 4 hours after isch 
emia. The lesion-induced hyperactivity continues for 
several days. Drugs that protect the animals from is 
chemia/reperfusion injury prevent the characteristic 
rise in spontaneous activity. PBN was effective at vari 
ous dosages in protecting against ischemia/reperfusion 
induced hyperactivity. as demonstrated by Table l and 
FIG. 1. It can be seen that saline treated animals given 
a 5 min ischemia insult had hyperactivity signi?cantly‘ 
higher than sham-operated controls 24 hr after isch 
emia. However. animals which had received PBX~ at 32 
or 100 mg/kg 1 hr prior to ischemia had no elevated 
hyperactivity. PBN at 300 mg/kg caused a decreased 
activity over controls. Data comparing activity at the 
2-1 hr reperfusion time of sham-operated controls with 1 
min ischemia. 5 min ischemia and 15 min ischemia le 
sioned animals. which had received either saline or 300 
mg/kg PBN. are shown in FIGS. 2. 3 and 4. The data 
clearly demonstrate that the high dose of PBN caused a 
reduction in ischemia induced hyperactivity to levels of 
the control or lower. 
TABLE 1 
Histopatholngical Scores in Gr3l’bll\ 7 days after 5 min 
of Global Cortical lschernia. 
Group Score 
Control (no ischemia) 4.? (:5) 
31 mg PEN/kg 2.5 (:7) 
100 mg PBX/kg‘ 2.8 (:4) 
i: 300 mg PBN/kg 
‘N = b gerbils per group. 
iJi 
In order to obtain parameters relative to acute toxic 
ity of PBN. total cumulative activity of normal gerbils 
were investigated at a wide range of concentrations. 
The data are shown in FIG. 5. Only at PBN concentra 
tions of 1000 mg/kg and higher was there any alteration 
in activity noted. PBN at 2000 mg/kg was not lethal to 
animals. The one noted effect at high PBN concentra~ 
tions is an induced lethargic response which disappears 
after 24 hours. ‘ 
The effect of PBN administration on percent survival 
of animals given lethal strokes (15 min ischemia) is 
shown in FIG. 6. 50% ofthe animals given 15 minutes 
ischemia died. With pre-ischemic treatment with PBX. 
100% of the animals survived. 
Ischemia/reperfusion induced oxidative damage to 
brain proteins. Gerbil brains which had received vari 
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ous treatments were analyzed for carbonyl groups on 
proteins. a measure of oxidative damage to protein. and 
glutamine synthetase activity. The results are shown in 
FIGS. 7 and 8 and compared in FIG. 9. 
FIG. 7 shows oxidative damage to protein as mea 
sured by carbonyl content as a percentage of a control 
gerbil brain given a ten minute ischemia at the indicated 
time of reperfusion. 300 mg PBN/kg was administered 
one hour prior to the onset of ischemia. Carbonyl pro 
tein content was elevated above control levels in 10 min 
ischemia treated brains without reperfusion. 
Reperfusion for 15 min did'not enhance carbonyl 
protein above the ischemia only values. After 60 min 
reperfusion there was a signi?cant increase in carbonyl 
proteinv PBN pretreatment prevented this rise. 
FIG. 8 shows the oxidative damage to glutamine 
synthetase activity as a percentage of a control gerbil 
brain given a ten minute ischemia at the indicated time 
of reperfusion. 300 mg PBN/kg was administered one 
hour prior to the onset of ischemia. Glutamine synthe- _ 
tase (GS) activity was slightly lower than control val 
ues after ischemia with no reperfusion. With increasing 
reperfusion time, there was a dramatic loss in GS activ 
ity such that after 60 min reperfusion, only 65% of the 
activity remained. PBN pretreatment of the animals 
prevented this loss in G5 activity. Since this enzyme is 
considered to be a glial cell marker, this data indicates 
post ischemic damage also occurs in glial cellsv 
FIG. 9 shows that there was a good correlation be 
tween the loss of GS activity versus accumulation of 
carbonyl protein when all of the samples analyzed are 
compared. 
Ischemia/Reperfusion Induced Gene Expression 
T_he levels of mRNA for c-fos and c-jun were exam 
ined in gerbil brain cortex after ischemia/reperfusion. 
The results of 10 min ofischemia followed by 60 min of 
reperfusion demonstrated that both c-fos and c-jun 
mRNA levels are elevated within 60 min after the in 
sult. Control animals and animals subjected to the sur 
gery showed lower levels of c-fos mRNA was mark 
edly enhanced. Pentobarbital pretreatment, which pro 
tects the animals from ischemia/reperfusion injury, 
prevented the induced expression of the c-fos gene, 
whereas no pretreatment caused a large increase in c-fos 
mRNA. PBN pretreatment suppresses the level of c-fos 
induction in the ischemia/reperfusion injury. 
Old gerbils are much more sensitive to‘ brain is 
chemia/reperfusion injury than young animals, as 
shown in Table 2. Data are expressed as number sur 
viving/total tested. 
TABLE 2 
Effects of PBN pretreatments on post reperfusion 
lethulitv in voung adult gerbils (3-4 months of age). 
Treatment Age (300 mg PBX/kg) Saline 
control young 15/15 15/15 
15 mm ischemia young 10/10 5/10‘ 
10 min ischemia retired 4/4 0/4 
breeders; (18 mo.) 
‘All \un'lvll'lg gerbils “ere \ubsequentl} tested for behtnitiral effects at 24 hr. 
post-ischemia. 
EXAMPLE 3 
Effectiveness of Spin-Trapping Reagents Other Than 
PBN 
In preliminary studies, the effectiveness of two other 
spintraps, DMPO and POBN, in preventing the acute 
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effects of an ischemic insult to brain was tested. The 
results indicate that both DMPO and POBN appear to 
offer some protection, but DMPO was less effective 
than POBN which was less effective than PBN. 
Modifications and variations ofthe present invention. 
compositions containing PBN and derivatives thereof, 
and methods using the compositions for the treatment 
of tissue damage resulting from ischemia or inflamma 
tion, will be obvious to those skilled in the art from the 
foregoing detailed description. Such modifications and 
variations are intended to come within the scope of the 
following claims. 
We claim: 
1. A method for in vivo treatment of oxidative CNS 
tissue damage resulting from ischemia or in?ammation 
comprising: 
providing a-phenyl t-butyl nitrone and derivatives 
thereof having spin trapping activity and prevent 
ing ATP depletion in vivo in tissue and 
a pharmaceutically acceptable carrier for delivery of 
the ot-phenyl t-butyl nitrone to the CNS of a pa 
tient. 
2. The method of claim 1 wherein the phenyl butyl 
nitrone derivatives are selected from the group consist 
ing of hydroxy PBNs, PBN esters. acetoxy PBNs. alkyl 
PBNs, alkoxyl PBNs, phenyl PBNs. 
3. The method of claim 1 wherein the PBN derivative 
is functionalized to release in vivo a compound selected 
from the group consisting of 2-. 3-. and 4-h_vdroxyphe-‘ 
nyl t-butyl nitrone; 2-. 3-. and 4-hydroxyphenyl t-but_vl 
nitrone; 2-, 3-, and 4-carboxyphenyl t-butyl nitrone; and 
2-. 3-. and 4-aminophenyl t-butyl nitrone. 
4. The method of claim 1 comprising as the active 
ingredient ot-phenyl t-butyl nitrone. 
5. The method of claim 1 further comprising adminis 
tering an agent selected from the group consisting of 
streptokinase. tissue plasminogen activator. mannitol. 
and lazaroids. 
6. The method ofclaim 1 wherein the PBX and deriv 
atives thereof is in a pharmaceutical carrier delivering 
an effective dosage to a patient to prevent reperfusion 
injury of CNS tissue. 
7. The method ofclaim 1 wherein the PBX and deriv 
atives thereof is in a pharmaceutical carrier delivering 
an effective dosage to a patient to prevent CNS tissue 
damage from in?ammation. 
8. The method of claim 1 wherein the PBN and deriv 
atives thereof is provided in a dosage of 10 to 300 mg 
PEN/kg body weight. 
9. The method of claim 1 wherein the composition is 
administered during or immediately after a stroke. 
10. The method of claim 1 wherein the composition is 
administered to a patient having a progressive neuronal 
disorder. 
11. The method of claim 1 wherein the composition is 
administered to a patient exposed to high pressure oxy 
gen or an oxygen enriched environment. 
12. The method ofclaim 1 wherein the composition is 
administered to a patient to mitigate damage to cells 
from exposure to a chemical agent. 
13. The method of claim 1 wherein the composition is 
administered to a patient suffering from meningitis. 
14. A composition for in vivo treatment of tissue 
damage resulting from ischemia or inflammation not 
associated with bacterial toxins comprising: 
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a-phenyl t-butyl nitrone and derivatives thereof hav 
ing spin trapping activity and preventing ATP 
depletion in vivo in tissue of the formula: 
H or 
\ / 
C=N+ 
/ \ 
X Y 
wherein: 
X is phenyl or 
(ORln 
wherein R is H, 
and n is a whole integer from 1 to 5: or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
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wherein W is C-CHg. NH-C-Z. 
0 
II II 
C-Cl-h. C-OZ. or Z: and 
Z is a C1 to C5 straight or branched alkyl group 
further comprising a compound selected from 
the group consisting of streptokinase. tissue plas 
minogen activator. mannitol and lazaroides 
a pharmaceutically acceptable carrier for intravenous 
administration to a patient, 
wherein the a-phenyl nitrone is in an amount effec 
tive to prevent tissue damage resulting from isch 
emia or in?ammation not associated with bacterial 
toxins wherein the nitrone and further compound 
are present in effective amounts. 
15. The composition of claim 14 wherein the phenyl 
butvl nitrone derivatives are selected from the group 
consisting of hydroxy PBNs‘ PBN esters. acetoxv 
PBNs. alkyl PBNs. alkoxyl PBNs. phen_\'l PBNs. 
16. The composition of claim 1 wherein the PBXY 
derivative is functionalized to release in vivo a com 
pound selected from the group consisting of 2-‘ 3-. and 
4-hydroxyphenyl t-butyl nitrone: 2-. 3. and 4-h_vdrox 
_vphenyl t-butyl nitrone: 2~. 3-. 3-. and 4-carboxyplienyl 
t~butyl nitrone; and 2-. 3-. and 4-aminophenyl t-butyl 
nitrone. 
17. The composition of claim 14 comprising as the 
active ingredient a-phen_vl t-but_vl nitrone. 
18. The composition of claim 14 wherein the PBX 
and derivatives thereof is in a pharmaceutical carrier 
delivering an effective dosage to a patient to prevent 
reperfusion injury. 
* 1k * * * 
